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Background: The emergence of Plasmodium falciparum resistance to artemisinin and its derivatives, manifested as
delayed parasite clearance following the treatment, has developed in Southeast Asia. The spread of resistance to
artemisinin from Asia to Africa may be catastrophic for malaria control and elimination worldwide. Recently, mutations in
the propeller domain of the Kelch 13 (k13) gene (PF3D71343700) were associated with in vitro resistance to artemisinin and
with delayed clearance after artemisinin treatment in southern Asia. The aim of the study was to characterize the genetic
variability of k13 and to evaluate the molecular resistance to artemisinin for the first time in Senegal.
Methods: Plasmodium falciparum isolates were collected from 138 malaria patients in Dakar and its districts during the
rainy season of October 2012 to January 2013 at the Hôpital Principal de Dakar. The k13 gene was amplified using nested
PCR and sequenced.
Results: A very limited variability within the k13 gene in Senegalese P. falciparum isolates was identified. No
polymorphism was detected in the six k13-propeller blades. Only two mutations, T149S (6.3%) and K189T (42.2%), and
one (N) or two (NN) asparagine insertion at the codon 142 (4.7 and 6.3%, respectively) were detected in the Plasmodium/
Apicomplexa-specific domain. None of the polymorphisms associated with artemisinin resistance in Southeast Asia was
detected in the 138 P. falciparum from Dakar.
Discussion: The present data do not suggest widespread artemisinin resistance in Dakar in 2012–2013. Notably, the
C580Y, R539T or Y493H substitutions that were associated with in vitro resistance or delayed parasite clearance in
Southeast Asia were not observed in Dakar, nor were any of the polymorphisms observed in parasites from Southeast
Asia, nor the M476I mutation that was selected in vitro with artemisinin pressure in a African parasite line.
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SenegalBackground
Malaria is transmitted in Dakar and its surrounding sub-
urbs with a spatial heterogeneity of the human biting
rate, which ranged from 0.1 to 250 bites per person per
night during the rainy season from 2007 to 2010 [1,2].
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article, unless otherwise stated.from 0.9 to 7.4% in asymptomatic women and children in
Dakar [3]. Morbidity in public health facilities decreased
from 17.9% in 2007 to 2.6% in 2008 in Dakar [4].
In 2006, the Senegalese National Malaria Control
Programme recommended artemisinin-based combination
therapy (ACT) as the first-line treatment for uncomplicated
malaria. The combination sulphadoxine-pyrimethamine
and amodiaquine treatment was changed to artemether-
lumefantrine and artesunate-amodiaquine. Since 2006,
more than 1.5 million ACT has been administered in
Senegal [5]. In 2006, the Senegalese National MalariaoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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pected cases of malaria with the P. falciparum histidine-
rich protein 2-based rapid diagnostic test. Since this time,
ACT use has been restricted to confirmed malaria cases to
reduce drug pressure. In 2009, 184,170 doses of ACT were
dispensed in Senegal [6]. In addition, the National Malaria
Control Programme also recommended the use of SP as
an intermittent preventive treatment (IPT), now named
seasonal malaria chemoprevention (SMC), during preg-
nancy and for children. However, the single use of SP as
seasonal IPT is inadvisable; for instance, SP must be used
in combination with amodiaquine, artesunate or pipera-
quine. Seasonal IPT with SP and one dose of artesunate
resulted in a 90% reduction in the incidence of clinical
malaria in Senegal [7,8].
However, the emergence of P. falciparum resistance to
artemisinin and its derivatives, manifested as delayed
parasite clearance following the treatment with artesu-
nate monotherapy or ACT, has developed in Southeast
Asia [9-12]. The spread of artemisinin resistance from
the Greater Mekong subregion to Africa may be cata-
strophic for malaria control and elimination around the
world. The spread of anti-malarial drug resistance from
Southeast Asia to Africa has previously happened with
chloroquine and SP [13,14]. Vigilant surveillance for re-
sistant parasites is warranted.
Recently, mutations in the propeller domain of the
kelch 13 (k13) gene were associated with in vitro resist-
ance to artemisinin and with delayed clearance after ar-
temisinin treatment in Southeast Asia [12,15-17]. The
aim of the study was to characterize the variability of
k13 gene for the first time in Senegal.
Methods
Patient and sample collection
Plasmodium falciparum isolates were obtained from pa-
tients diagnosed with malaria, who live in Dakar and its
districts (>90%) and did not travel during the previous
month, during the rainy season of October 2012 to Janu-
ary 2013 (138 patients, 37% female). The patients with
malaria were recruited at the Hôpital Principal de Dakar, a
military hospital. Venous blood samples were collected in
Vacutainer® ACD tubes (Becton Dickinson, Rutherford,
NJ, USA) prior to patient treatment. Of the 138 patients,
57% were recruited from the emergency department and
other patients were recruited from the intensive care unit
(20%), maternity department (7%), infectious diseases de-
partment (5%), paediatric department (3%) and other units
(8%). Information on anti-malarial treatment prior to ad-
mission was not available. Informed verbal consent from
the patients and/or their parents/guardians was obtained
before blood collection; the study was approved by the
ethical committee of the Hôpital Principal de Dakar. Thin
blood smears were stained using a RAL® kit (Réactifs RAL,Paris, France) and were examined to determine P. fal-
ciparum density and to confirm monoinfection by P.
falciparum.
Evaluation of k13-propeller polymorphisms was per-
formed using the same venous blood sample used for this
diagnostic analysis. The patients were successfully treated
with quinine (98%) and artemether-lumefantrine (2%).
Analysis of Plasmodium falciparum isolates
The total genomic DNA of each isolate was extracted
using the QIAamp® DNA Mini kit according to the man-
ufacturer’s recommendations (Qiagen, Germany). The
k13-propeller gene was amplified by PCR using the fol-
lowing primers: for the primary PCR (K13_PCR_F 5’-G
GGAATCTGGTGGTAACAGC-3’ and K13_PCR_R 5’-C
GGAGTGACCAAATCTGGGA-3’) and for the nested
PCR (K13_N1_F 5’-GCCTTGTTGAAAGAAGCAGA-3’
and K13_N1_R 5’-GCCAAGCTGCCATTCATTTG-3’)
[15]. For primary PCR, 5 μL of genomic DNA were
amplified with 1X final of reaction buffer (Eurogentec,
Belgium), 200 μM of a deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Eurogentec,
Belgium), 2.5 mM MgCl2, 250 nM of each primer and
1.25 U Red Diamond Taq® polymerase (Eurogentec,
Belgium) to a final volume of 25 μl. The thermal cycler
(T3 Biometra, Archamps, France) was programmed as fol-
lows: 15 min at 95°C, then 30 cycles of 30 sec at 95°C,
2 min at 58°C, 2 min at 72°C and final extension 10 min at
72°C. For the nested PCR, 5 μL of primary PCR amplicons
were amplified under the same conditions with two U Red
Diamond Taq® polymerase (Eurogentec, Belgium) to a
final volume of 50 μl. The PCR thermocycling conditions
were: 15 min at 95°C, then 40 cycles of 30 sec at 95°C,
1 min at 60°C, 1 min at 72°C and final extension 10 min
at 72°C.
The sequencing reaction contained 4 μl of BigDye Ter-
minator® v3.1 mix (Life Technologies, CA, USA), 0.8 μM
of primer described above, and 4 μL PCR amplicon in a
total of 20 μl volume. The cycle conditions were initial de-
naturation at 96°C for 5 min followed by 30 cycles at 96°C
for 10 sec, 50°C for 5 sec, and 60°C for 4 min. Excess dye
terminators were removed with a BigDye XTerminator®
Purification Kit (Life Technologies, CA, USA). The sam-
ples were loaded on an ABI Prism 3100 analyzer (Applied
Biosystems) according to the manufacturers’ instructions.
The sequences were analysed using Vector NTI advance
(TM) software (version 11, Invitrogen, Cergy Pontoise,
France) to identify specific single nucleotide polymorph-
ism (SNP) combinations.
Results
The entire k13 gene was successfully sequenced in 64/
138 P. falciparum isolates. The propeller domain gene
was successfully in the 138 malaria episodes diagnosed
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reference 3D7 strain (PF3D7_1343700 reference coding
sequence), the SNPs observed were shown in Table 1.
The polymorphisms T149S (6.3%) and K189T (42.2%)
were not found in same isolates. The K189T mutation
was found in two out of the three isolates with one as-
paragine (N) insertion (NN at codon 142). Notably, the
C580Y, R539T or Y493H substitutions that were associ-
ated with in vitro resistance or delayed parasite clearance
in Southeast Asia were not observed in Dakar, nor were
any of the polymorphisms observed in parasites from
Southeast Asia, nor the M476I mutation that was se-
lected in vitro with artemisinin pressure.
Discussion
The emergence of P. falciparum resistance to artemisi-
nin and its derivatives, manifested as delayed parasite
clearance following the treatment with artesunate mono-
therapy or ACT, has recently developed in Southeast
Asia [9,12]. This clinical resistance was correlated with
in vitro resistance, manifested by an increase in the ring-
stage survival rate after contact with artemisinin [18,19].
Mutations in the P. falciparum k13 gene that encodes the
kelch propeller domain were associated with in vitro re-
sistance to artemisinin and with delayed clearance after ar-
temisinin treatment in Southeast Asia [12,15-17]. These
works reported an in vitro artemisinin resistance associ-
ated with the M476I mutation in k13-propeller gene in
African genetic background parasite (F32 Tanzania) that
was selected in vitro with artemisinin pressure, a pro-
longed parasite ex vivo survival associated with the
Y493H, I543T, R539T, and C580Y mutations, and an
in vivo delayed parasite clearance associated with the
Y493H, R539T and C580Y mutations. In addition, a recent
report supports the causal role of k13-propeller mutations
in conferring resistance to artemisinin, and specially the
role of the C580Y mutation by genome manipulation
[20]. The mutation C580Y was introduced in the gen-
ome of a P. falciparum strain susceptible to artemisinin
using the CRISPR-Cas9 system, and consequentlyTable 1 Polymorphisms observed in the K13 gene in 138
Plasmodium falciparum isolates from Dakar, Senegal
collected from October 2012 to January 2013
Codon position Amino acid
reference
Amino acid mutation or
asparagine insertion
n/N (%)
142 N NN 3/64 (4.7%)
142 N NNN 4/64 (6.3%)
149 T S 4/64 (4.7%)
189 K T 27/64 (42.2%)
All data are relative to the PF3D7_1343700 reference coding sequence.
n = number of samples with mutant allele or insertion.
N = number of samples sequenced at locus.increased the ring-stage parasite survival in presence of ar-
temisinin. However, the presence of multiple, population-
specific mutations responsible for artemisinin resistance
leads to independent emergence of resistance in multiples
geographic locations in Southeast Asia [12,17].
None of the polymorphisms associated with artemisinin
resistance in Southeast Asia were detected in the 138 P.
falciparum isolates from Dakar. A very limited variability
was identified within the k13 gene in Senegalese P. falcip-
arum isolates. No polymorphism was detected in the six
k13-propeller blades. Only two mutations, T149S and
K189T, and an insertion of N or NN at codon 142 were
detected in the Plasmodium/Apicomplexa-specific do-
main. The K189T mutation was present in 42.2% of the
samples. This mutation was previously found in 34.4%
(10/29) of the isolates tested in Uganda [21] and in one
isolate in Bangladesh [17]. Among the 20 isolates with
K189T mutation (unknown location of collection) previ-
ously found, all except one were associated with parasite
clearance half-life <5 hours [12]. This cut-off of 5 hours
was determined on the basis of 90th centile for parasite
clearance half-life in 2004 when resistance had just
emerged in the Thailand-Myanmar border. However, par-
asites clearance rates are still influenced by many factors,
including pharmacokinetics of anti-malarial drugs as well
as host-immunity. A shorter cut-off needs to be consid-
ered for studies in settings of high transmission where pa-
tient immunity might be at a higher level. In Bangladesh,
the only one isolate with K189T mutation was associated
with parasite clearance half-life >5 hours [17]. The isolates
with T149S mutation (unknown location of collection)
previously found were associated with parasite clearance
half-life <5 hours [12]. The role of these two mutations is
not well established although these mutations seem to be
associated with parasite clearance half-life <5 hours. Fur-
ther studies are needed to better characterize these varia-
tions. However, the absence of putative P. falciparum
artemisinin resistance mutations in Senegal is consistent
with the efficacy of ACT in Senegal [22,23].
The polymorphisms associated with artemisinin re-
sistance in Southeast Asia were not detected in other
countries in Africa with the exception of the P553L
which was detected in one isolate in Mali [12,23,24]. In
Uganda, the prevalence of k13-propeller polymorphisms
was not associated with the persistence of parasites after
two days following treatment with artemether-lumefantrine
[21]. However, due to the high baseline parasitaemia in
Uganda, persistent parasitaemia two days after the onset of
therapy is likely not a reliable indicator of resistance in
Uganda. When artemisinin resistance will emerge in Africa,
it may be due by the spread of resistant parasites imported
from Southeast Asia and/or by selecting for de novo evolu-
tion of resistance (uncommon mechanisms between Asia
and Africa).
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sites populations from West Africa (Gambia, Mali, Ghana,
Burkina Faso), Central Africa (Democratic Republic of
Congo) and East Africa (Kenya, Tanzania, Malawi) was not
detected in Dakar [23]. This mutation was not found in
Uganda [24].
These results are encouraging and suggest that artemi-
sinin resistance is not yet established in Senegal. None
of the mutations that are associated with artemisinin re-
sistance in Southeast Asia are found in Africa [21,24].
However, numerous novel k13 propeller coding poly-
morphisms circulate in Africa. The phenotypes of these
coding substitutions are unknown and will require fur-
ther characterization to better characterize the clinical
impact in artemisinin resistance in Africa.
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